CPHI Annual Report Predicts VC Capital (re)Entry and Contract Services Growth in 2024

Data points to the “bottom being in” and for 2024 to be significantly better for growth, valuations, and capital.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

New research from the CPHI Annual Report 2023—launched during CPHI Barcelona, the world’s largest pharma event, held at Fira Barcelona (October 24-26th, 2023)—points to an uplift ahead for biotech funding and a consequential follow through of growth for pharma contract services. Analysis was provided by CPHI Report expert, Brian Scanlan of Edgewater Capital, who states that liquidity in the biotech and mid-sized pharma market is typically a proxy of growth for the CRO/CDMO sector. Significant...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters